---
schema_version: "secwatch.filing_event.v1"
accession: "0001567264-24-000053"
form_type: "8-K"
ticker: "INTS"
cik: "0001567264"
company_name: "INTENSITY THERAPEUTICS, INC."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:54:53.495077+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Intensity Therapeutics Q3 net loss $3.5M; first patient dosed in Phase 2 TNBC study

## Summary
- Net loss of $3.5M for Q3 2024 vs $2.3M a year ago; R&D expenses rose to $2.2M.
- Cash and equivalents $2.8M as of Sept 30, 2024; expected to fund operations into Q1 2025.
- First patient dosed in Phase 2 INVINCIBLE-4 study of INT230-6 in presurgical triple-negative breast cancer.
- Phase 3 INVINCIBLE-3 sarcoma study received regulatory authorizations in 8 countries; enrollment target 333 patients.
- Regulatory approvals obtained from Health Canada, EMA, Swissmedic, and Australia's TGA during Q3 2024.

## SEC filing metadata
- accession: 0001567264-24-000053
- form_type: 8-K
- ticker: INTS
- cik: 0001567264
- company_name: INTENSITY THERAPEUTICS, INC.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567264/000156726424000053/0001567264-24-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567264/000156726424000053/intensity-20241113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001567264-24-000053
- JSON: https://secwatch.observer/filing/0001567264-24-000053.json
- Plain text: https://secwatch.observer/filing/0001567264-24-000053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.